IN8bio Inc (INAB) concluded trading on Thursday at a closing price of $0.15, with 6.59 million shares of worth about $0.99 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -51.70% during that period and on May 29, 2025 the price saw a gain of about 8.03%. Currently the company’s common shares owned by public are about 81.26M shares, out of which, 71.27M shares are available for trading.
Stock saw a price change of 21.75% in past 5 days and over the past one month there was a price change of -10.81%. Year-to-date (YTD), INAB shares are showing a performance of -40.36% which decreased to -84.81% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.11 but also hit the highest price of $1.74 during that period. The average intraday trading volume for IN8bio Inc shares is 1.41 million. The stock is currently trading 2.65% above its 20-day simple moving average (SMA20), while that difference is down -8.45% for SMA50 and it goes to -45.36% lower than SMA200.
IN8bio Inc (NASDAQ: INAB) currently have 81.26M outstanding shares and institutions hold larger chunk of about 17.96% of that.
The stock has a current market capitalization of $13.92M and its 3Y-monthly beta is at 0.17. It has posted earnings per share of -$0.49 in the same period. It has Quick Ratio of 4.30 while making debt-to-equity ratio of 0.31. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for INAB, volatility over the week remained 5.35% while standing at 4.87% over the month.
Stock’s fiscal year EPS is expected to rise by 63.86% while it is estimated to decrease by -3.88% in next year. EPS is likely to grow at an annualized rate of 23.77% for next 5-years, compared to annual growth of -13.22% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Laidlaw on March 18, 2024 offering a Buy rating for the stock and assigned a target price of $7.50 to it. Coverage by H.C. Wainwright stated IN8bio Inc (INAB) stock as a Buy in their note to investors on August 30, 2022, suggesting a price target of $14 for the stock.
